Protara Reports Q2 Cash of $162M, Advances Bladder Cancer and Rare Disease Programs
TARA sits 34% above its 52-week low of $2.97.
Summary
Protara's Q2 update reveals a cash position of $162 million, down from $177.4 million at Q1, but still funding operations into 2028. The company is redesigning its ADVANCED-3 bladder cancer trial to an exploratory multi-cohort study, aiming to accelerate data in a broader patient population ahead of a potential TARA-002 launch. Updated STARBORN-1 data in lymphatic malformations showed 83% clinical success, and the FDA engagement supports a BLA submission in the second half of 2027. THRIVE-3 interim results for IV Choline Chloride are on track for Q4 2026. The pipeline progress and regulatory clarity strengthen the outlook, though cash burn remains a factor.
At the time of this announcement, TARA was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $231M. The 52-week trading range was $2.97 to $7.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.